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This work was initiated by previous reports demonstrating that mismatched influenza 
A virus (IAV) vaccines can induce enhanced disease, probably mediated by antibodies. 
Our aim was, therefore, to investigate if a vaccine inducing opsonizing but not neutral-
izing antibodies against the hemagglutinin (HA) of a selected heterologous challenge 
virus would enhance disease or induce protective immune responses in the pig model. 
To this end, we immunized pigs with either whole inactivated virus (WIV)-vaccine or 
HA-expressing virus replicon particles (VRP) vaccine based on recombinant vesicular 
stomatitis virus (VSV). Both types of vaccines induced virus neutralizing and opsonizing 
antibodies against homologous virus as shown by a highly sensitive plasmacytoid 
dendritic cell-based opsonization assay. Opsonizing antibodies showed a broader 
reactivity against heterologous IAV compared with neutralizing antibodies. Pigs immu-
nized with HA-recombinant VRP vaccine were partially protected from infection with a 
mismatched IAV, which was not neutralized but opsonized by the immune sera. The 
VRP vaccine reduced lung lesions, lung inflammatory cytokine responses, serum IFN-α 
responses, and viral loads in the airways. Only the VRP vaccine was able to prime 
IAV-specific IFNγ/TNFα dual secreting CD4+ T cells detectable in the peripheral blood. 
In summary, this work demonstrates that with the virus pair selected, a WIV vaccine 
inducing opsonizing antibodies against HA which lack neutralizing activity, is neither 
protective nor does it induce enhanced disease in pigs. In contrast, VRP-expressing 
HA is efficacious vaccines in swine as they induced both potent antibodies and T-cell 
immunity resulting in a broader protective value.
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Table 1 | Viruses used in this study.
Full name subtype short name source
A/swine/Bakum/IDT1769/2003 H3N2 IDT1769/03 FLI
A/swine/Bakum/R325/2009 H3N2 R325/09 FLI
A/swine/Bakum/R757/2010 H1N2 R757/10 FLI
A/swine/Germany-BB/siv-leipz11308/09  H1N1 Leipzig/09 FLI
A/swine/Belzig/2/01 H1N1 Belzig/01 FLI
A/swine/Belgium/1/98 H1N1 Belgium/98 UGent
A/swine/Bülow/1/81 H1N1 Bülow/81 UGent
A/California/04/2009 H1N1 California/09 HUG
A/swine/Gent/7625/99 H1N2 Gent/99 UGent
A/swine/Flanders/1/98 H3N2 Flanders/98 UGent
A/New Caledonia/20/99 H1N1 NC/99 HUG
A/swine/Wessin/2009 H1N1 Wessin/09 FLI
A/swine/Iowa/15/30 H1N1 Iowa/30 ATCC
A/swine/Germany/R248/2010 H1N1 R248/10 FLI
2
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inTrODUcTiOn
Influenza A virus (IAV) is a negative-sense RNA virus of the 
family Orthomyxoviridae. The genome is composed of 8 gene 
segments coding for 11 gene products. The natural reservoir for 
IAV is wild waterfowl, but distinct IAV lineages also exist in pigs, 
horses, dogs, sea mammals, bats, and humans (1–3). IAV from 
animal origin have zoonotic potential and may adapt to human 
hosts. The enormous genetic plasticity of these viruses facilitates 
this process.
The hemagglutinin (HA) is the most abundant and impor-
tant antigen of the IAV envelope. It induces virus-neutralizing 
antibodies that interfere with either receptor-binding membrane 
fusion or viral egress (4, 5). Therefore, HA is the prime antigen of 
influenza virus vaccines. However, HA is subject to antigenic drift 
caused by point mutations and antigenic shift caused by segment 
exchange, and both processes result in mutant viruses that may 
escape pre-existing immunity. For this reason, licensed inacti-
vated virus vaccines, which induce immunity mainly through 
their ability to induce neutralizing antibodies, must match the 
currently circulating field viruses. Of additional concern is that 
in some cases pre-existing immunity against heterologous IAV 
strains can even lead to enhanced disease, as observed in human 
and pigs (6–10). A study in humans suggested that enhanced 
disease is associated with immune complexes involving non-
neutralizing antibodies (11). However, the role of individual viral 
proteins in this process has not been investigated.
Consequently, using an HA-expressing vesicular stomatitis 
virus (VSV) vector and a whole inactivated virus (WIV) vaccine, 
this study addressed if vaccines selected to induce opsonizing but 
not neutralizing antibodies against a heterologous H1N1 porcine 
IAV strain would confer enhanced disease or protection. While 
we did not find any evidence for enhanced disease, pigs were 
partially protected if they had received the VSV vaccine, which 
induced both opsonizing and IAV-specific dual-functional CD4 
T helper cells.
MaTerials anD MeThODs
cells
BHK-21 cells were (ATCC, Manassas, VA, USA) grown in 
Earle’s minimal essential medium (MEM) (Life Technologies, 
Zug, Switzerland) supplemented with fetal bovine serum (FBS) 
(Biowest, Nuaillé, France). BHK-G43, a transgenic BHK-21 cell 
clone expressing the VSV G protein, was maintained, as described 
previously (12). Madin–Darby canine kidney (MDCK; ATCC) 
cells were propagated in MEM supplemented with 10% FBS, 
non-essential amino acids (Life Technologies), and 1 mM sodium 
pyruvate (Life Technologies).
Viruses
The viruses used are summarized in Table  1. All IAV were 
propagated in 10-day-old embryonated specific-pathogen-free 
(SPF) chicken eggs incubated for 2 days at 37°C. IAV were titrated 
on confluent MDCK cells in presence of 1 μg/ml of acetylated 
trypsin (Sigma-Aldrich). After 24 h, cells were fed by addition of 
new medium, and 48 h post-infection (p.i.), the cells were fixed 
with 4% paraformaldehyde (Polysciences, Warrington, PA, USA). 
The plates were stained with anti-NP antibody (HB-65, ATCC) 
in saponin (Sigma-Aldrich), followed by horseradish peroxidase-
conjugated goat anti-mouse antibody (Dako, Baar, Switzerland), 
and a final color reaction with 3-amino-9-ethylcarbazole (AEC, 
Sigma-Aldrich). Titers were calculated using the Reed and 
Muench formula.
Plasmids
The cDNAs encoding HA or NA of H1N1 A/swine/Belzig/2/01 
(Belzig/01) were kindly provided by Drs. Jürgen and Olga 
Stech (Friedrich-Loeffler-Institute, Riems, Germany) (13). The 
open reading frames of IAV antigens were amplified by PCR 
and cloned into the pVSV* plasmid using the MluI and BstEII 
endonuclease restriction sites placed upstream and downstream 
of the fourth transcription unit of the VSV genome (14). To 
facilitate titrations, a cDNA encoding enhanced green fluorescent 
protein (eGFP) was inserted into an additional transcription unit 
located in the intergenic region between the original G and L 
genes. The resulting plasmids were designated pVSV*ΔG(H1) 
and pVSV*ΔG(N1), in which the asterisk denotes the pres-
ence of the eGFP gene and ΔG indicates the absence of the 
glycoprotein G gene.
generation of VrP
Virus replicon particles (VRP) lacking the envelope glycoprotein 
G were generated, as described previously (14, 15). Briefly, BHK-
G43 cells were infected with recombinant MVA-T7 expressing 
T7 RNA polymerase (16) and subsequently transfected with a 
plasmid carrying a VSV anti-genomic cDNA, along with three 
plasmids encoding the VSV proteins N, P, and L. All genes were 
placed under the control of the T7 promoter. Expression of the 
VSV G protein was induced in BHK-G43 cells by adding 10−9M 
mifepristone (Sigma-Aldrich) to the culture medium. At 24  h 
post-transfection, the cells were trypsinized and seeded into T75 
cell culture flasks (Corning B.V., Amsterdam, The Netherlands), 
along with an equal number of fresh BHK-G43 cells. The cells 
were incubated at 37°C for 24 h in the presence of mifepristone. 
The cell culture supernatant was clarified by low-speed centrifuga-
tion and passed through a 0.20-μm pore-size filter. Recombinant 
3Ricklin et al. Protection against Influenza Virus by VRP-Expressing Hemagglutinin
Frontiers in Immunology | www.frontiersin.org June 2016 | Volume 7 | Article 253
viruses were propagated on mifepristone-induced BHK-G43 
cells to generate VRP, which were titrated on BHK-21. Infectious 
titers were expressed as fluorescent focus-forming units (FFU) 
per milliliter.
animal experiments
The animal experiments were performed according to local 
law and were approved by the Cantonal Ethical Committee for 
Animal Experiments (BE 07-12). In total, 31 healthy 7-week-old 
Swiss Large White pigs (18 castrated males and 13 females) from 
our SPF breeding facility were used. Animals were housed in 
groups of ≥3 inside the containment facility of the Institute for 
Virology and Immunology (IVI) representing a BSL3-Ag facility. 
Prior to the infection, they were allowed 1 week of adaptation to 
the new environment.
To produce protein-specific antisera, two pigs per vac-
cine were immunized with VSV*ΔG (negative control), 
VSV*ΔG(H1), and VSV*ΔG(N1) into the gluteal and deltoideal 
muscle with a dose of 108 TCID50 in a volume of 4  ml, fol-
lowed by a boost 4  weeks later. Two additional piglets were 
vaccinated with binary ethyleneimine (BEI) inactivated Belzig 
Virus (WIV) composed of 5.3 ×  106 TCID50 in a volume of 
4 ml, formulated with 15% of Montanide 25VG (kindly donated 
by Seppic, Puteaux, France). The selection of this adjuvant was 
based on its known potency to induce antibody responses with 
inactivated virus preparations. Animals were bled weekly, and 
sera were frozen at −20°C.
For the vaccination/challenge experiment, animals were 
vaccinated in groups of five with VSV*ΔG, VSV*ΔG(H1), 
VSV*ΔG(N1), or WIV, as described earlier. After 4 weeks, an 
identical booster vaccination was done. Animals were exam-
ined clinically daily, and blood was taken once a week. Three 
weeks post-boost, all pigs were challenged intratracheally with 
7 × 106 TCID50 of H2N1 A/swine/Bakum/R757/2010 (R757/10) 
under general anesthesia with 0.5  mg/kg Midazolam (Roche, 
Reinach, Switzerland) and 10 mg/kg Ketamin (Provet, Lyssach, 
Switzerland). After challenge, all animals were clinically exam-
ined daily, including measuring body temperature, and assess-
ing awareness, appetite, manure excretion, breathing, coughing, 
skin color, and gait. Blood and oronasal swabs were taken daily. 
After 24  h, each animal was bronchoscopied, and bronchoal-
veolar lavage fluid was collected of both lung halves with 20 ml 
PBS under general anesthesia. Day 3 post-challenge pigs were 
euthanized by electroshock and subsequent exsanguination. 
Sampling was performed immediately after exsanguination 
and included swabs, blood for serum, and organs for RT-PCR 
and histology.
Virological analyses
Of each animal, all four cranial lobes and a bronchial lymph 
node were collected into 1.5 ml tubes containing 500 μl MEM 
medium (Life Technologies) and weighed before lysing with 
a BulletBlender® (Next Advanced Inc., Averill Park, NY, USA). 
Lysed organs were centrifuged, and the supernatants transferred 
into new tubes and stored −70°C. RNA was extracted using the 
QIAmp® viral RNA extraction kit (Qiagen AG, Hombrechtikon, 
Switzerland) according to manufacturer’s instructions and ampli-
fied by quantitative reverse transcriptase polymerase chain reac-
tion (RT-qPCR) using primers and probe, as described (17, 18). 
The RT-qPCR was performed as published using the SuperScript® 
III Platinum® One-Step RT-qPCR Kit (Life Technologies) and run 
on a 7900HT Thermocycler (Applied Biosystems) for 50 cycles. 
Mean Cq values were determined from triplicates. For absolute 
RNA quantification, an internal standard was used based on M1 
genome copies (17, 18).
serological assays
For virus neutralization tests (VNT), sera were serially diluted 
in triplicates starting at a 1:5 dilution in virus growth medium 
(MEM, supplemented with HEPES and TPCK trypsin). One 
hundred TCID50/well of IAV were added, and the mix was gently 
agitated and incubated at 37°C for 30 min. Confluent MDCK cells 
were then incubated with the serum-virus mix at 37°C, and after 
24 h, 100 μl medium was added in each well. After another 24 h, 
the cells were fixed and stained as described earlier, and VNT 
titers were read as the last serum dilution that prevented infec-
tion. As anti-NA antibodies do not neutralize but prevent cell-to-
cell spread, the titer of sera obtained from animals immunized 
with NA only was defined as the last dilution able to inhibit viral 
spread resulting only in single cell infections. Plaque reduction 
assays were performed as VNTs with the following modifications. 
Only 50 μl of serum/virus mix was added to MDCK cells and 
incubated for 6 h at 37°C. Then, 150 μl of 0.8% methylcellulose 
(Sigma-Aldrich) medium were added to each well and incubated 
for another 36 h before harvest.
To identify antibodies reactive with HA or NA expressed on 
the surface of infected cells, MDCK cells were infected for 12 h 
with IAV, fixed, and stained with the immune sera followed by 
an fluorochrome-conjugated goat anti-pig antibody (Bethyl, 
Montgommery, TX, USA) and analyzed by flow cytometry 
(FACSCalibur, BD Biosciences, Allschwil, Switzerland).
For opsonization assays, we made use of a previously 
established assay based on the ability of plasmacytoid dendritic 
cells (pDCs) to secrete enhanced INF-α in response to immune 
complexed virus compared with free virus via an Fcγ receptors 
(FcγR)-dependent pathway (19–21). To this end, peripheral 
blood mononuclear cells (PBMCs) were freshly isolated from 
blood of our SPF pigs using ficoll-paque density centrifugation 
(1.077 g/l, Amersham Pharmacia Biotech). pDCs were enriched 
by cell sorting of CD172a+ PBMCs using the magnetic cell sort-
ing system (MACS) with LD columns (Miltenyi Biotec GmbH, 
Germany), as described previously (19). This permits a 10- to 
20-fold enrichment of pDC. IAV were then first titrated on pDC 
to find virus doses inducing low levels of pDC activation by the 
virus alone. As this is highly variable with different strains of 
IAV (22), the optimal doses were determined with each virus 
isolate and for each virus stock to be employed. Then, sera were 
serially diluted in DMEM supplemented with 1% porcine SPF 
serum and 50 μM β-mercaptoethanol, followed by incubation 
with the determined viral dose and incubated for 20 min at 39°C. 
Enriched pDCs were then added, and the cultures incubated for 
16 h at 37°C. Supernatants were tested for IFN-α by ELISA (19). 
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Virus opsonizing titers were defined as the highest serum dilution 
resulting in a significantly higher IFN-α production compared 
with naive serum.
Pathology
For the macroscopic scoring, pneumonic lesions character-
ized by increased redness and consolidation of lung tissue 
were scored according to the following scheme: ventral and 
dorsal aspects of the cranial lobe received a maximum of 5 
points each, ventral aspects of the caudal lobes a maximum of 
12.5 points, dorsal aspects of the caudal lobes 15 points, and 
accessory lobes (ventral aspects only) a maximum of 5 points. 
All points were summed up to a total macroscopic score. For 
histological examination, cranial lobes were fixed in 10% 
buffered formalin, processed routinely for paraffin embedding, 
cut at 5 μm, and stained with hematoxylin and eosin (H&E). 
A board certified pathologist scored all histological sections 
in a blinded manner. Bronchi and bronchioles were scored 
for epithelial necrosis, fibrin exsudation, and infiltration with 
neutrophils. Alveoli were scored for epithelial necrosis, fibrin 
exsudation, hemorrhage, neutrophilic infiltration, thickening 
of the alveolar walls, and atelectasis. The following scores were 
given to each of the abovementioned findings: 0 = no lesions; 
1 =  very mild lesions (<5% of structures affected), 2 =  mild 
lesions (5–20% of structured affected), 3 =  moderate lesions 
(20–40% of structures affected), 4 = severe lesions (40–60% of 
structured affected), and 5 =  very severe lesions (more than 
60% of structures affected). All scores were summed up to a 
total microscopic lung score.
T cell assays
Peripheral blood mononuclear cells were thawed and cultured 
in AIM medium Albumax (Gibco) with 2% FBS and stimulated 
with IAV (Belzig/01 or R757/10) MOI 0.1 TCID50/cell or a cor-
responding volume of chicken allantoic fluid (CAF) for 15  h 
at 39°C. Brefeldin A (ebioscience, San Diego, CA, USA) was 
added for another 4  h before harvest. Cells were first stained 
with Fixable Aqua Dead Cell Stain kit (ThermoFisher, Waltham, 
MA, USA). Then, surface staining employed anti-CD4 IgG2b 
(74-12-4) and anti-CD8β IgG2a (PG164A; VMRD, Pullmann, 
WA, USA), followed by isotype-specific Alexafluor-488 and 
PE-Cy7 fluorochrome conjugates (Thermofisher and Abcam, 
respectively). After fixation and permeabilization, anti-IFNγ-PE 
(P2G10, BD Biosciences) and anti-TNFα-AF647 (Mab11, 
Biolegend, San Diego, CA, USA) were added. Cells were analyzed 
by flow cytometry (FACSCanto). Dead cells were excluded, fol-
lowed by doublet discrimination, and gating on CD4 and CD8 
and single positive cells to determine their intracellular IFNγ 
and TNFα expression.
statistical analysis
For multiple group comparisons one-way ANOVA, for pair 
comparisons two-way Mann–Whitney U test, and for non-pair 
comparisons Wilcoxon test were used. p < 0.05 was considered 
significant. The Graph Pad Prism software (GraphPad software, 
La Jolla, CA USA) was employed.
resUlTs
neutralizing activity and cross-reactivity 
of antibodies induced by VrPs expressing 
h1 and n1
The first aim of this study was to characterize anti-HA and 
anti-NA antibodies with respect to their neutralizing activity 
against various IAV. To this end, we immunized pigs with 
VSV*ΔG(H1) or VSV*ΔG(N1) VRPs expressing the HA and 
NA antigens of A/swine/Belzig/2/01 (H1N1) (Belzig/01). 
Control animals received the VSV*ΔG VRP only expressing 
GFP but not any influenza antigen. As a reference vaccine, 
WIV prepared from a Belzig/01 was used. None of the animals 
showed any adverse effects in response to the VRP vaccines, 
but the two pigs vaccinated with WIV had a transient increase 
of body temperature by 0.5°C for 1 day, both following prime 
and booster injection.
The immune sera from vaccinated pigs obtained 3 weeks after 
the booster vaccination were analyzed for both neutralizing and 
opsonizing activity in order to identify a virus, which could be 
opsonized but not neutralized. To this end, we first performed 
VNTs with a collection of porcine and human H1N1 IAV as 
well as porcine H1N2 and H3N2 IAV (Figure  1A). Sera from 
pigs vaccinated with VSV*ΔG(H1) had titers of 1:1280 against 
the homologous virus and two others H1N1 viruses of the same 
subgroup (R248/10 and Belgium/98). The titers for Leipzig/09 
and Iowa/30 were 160, while all other viruses were not or only 
weakly neutralized including two isolates from the 2009 pan-
demic (Wessin/09 and California/09). A low level of neutraliza-
tion was also found against Gent/99 (H1N2). These results were 
confirmed by a plaque reduction test (data not shown).
Sera obtained from pigs vaccinated with the VSV*ΔG(N1) 
were tested for their ability to inhibit viral spread using the same 
collection of viruses (Figure  1B). Spread of the homologous 
virus and R248/10 was still inhibited at a serum dilution of 
1:1280. Overall, anti-N1 sera showed a broader reactivity against 
different N1 viruses with the exception of Bülow/81, which was 
not inhibited. N2 viruses were not inhibited by anti-N1 serum 
with the notable exception of IDT1769/09, which was inhibited 
to some extent.
Opsonizing activity of anti-h1  
and anti-n1 antibodies
Our next aim was to identify viruses, which were opsonized by 
immune sera in the absence of virus neutralizing activity. To 
this end, an assay was employed that was based on the ability 
of immune serum to enhance IAV-induced INF-α secretion 
from pDCs. The anti-H1, anti-N1, and anti-WIV sera were all 
able to opsonize the homotypic virus at dilutions ranging from 
10−3 to 10−5 (Figure  1C). The heterotypic Wessin/09 (H1N1) 
was not opsonized by anti-H1 sera, but was opsonized by sera 
from pigs vaccinated with VSV*ΔG(N1) and WIV at dilutions 
ranging from 10−3 to10−4 (Figure 1D). Using the H1N2 viruses 
R757/10 and Gent/99, enhanced INF-α was found with serum 
from pigs vaccinated with VSV*ΔG(H1) or WIV, but not with 
anti-N1 serum. The serum dilutions were ranging from 10−2 to 
FigUre 1 | Functional characterization and cross-reactivity of sera from vaccinated pigs. (a) Neutralizing activity against various IAV of anti-HA sera from 
pigs that were vaccinated with VSV*ΔG(H1) of Belzig/01. (b) Inhibitory activity of anti-NA sera from pigs vaccinated with VSV*ΔG(N1) of Belzig/01 against virus 
spread in cell culture. (b). In (a,b), titers were defined as the last serum dilution that inhibited infection or allowed only single cell infection. The sera were collected 
3 weeks after the second booster immunization. Mean and SD of six replicates from a representative experiment out of two is shown. (c–h) Different viruses were 
tested in a pDC-based opsonization assay based for antibody-enhanced pDC activation and IFNα secretion following stimulation with immune complexes. Sera 
from naive, VSV*ΔG(H1), VSV*ΔG(N1), and WIV vaccinated pigs were serially diluted and tested for their ability to enhance IFNα of pDC stimulated by various IAV. 
A representative experiment is shown. (i–K) Mean and SD of all pDC-based opsonization assays performed. Opsonizing titers were defined as the highest serum 
dilution resulting in a significantly higher IFN-α production by enriched pDC as compared with naive serum. Each symbol represents an independent experiment. 
Asterisks (*) indicate significant differences calculated with the Wilcoxon test (p < 0.05).
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FigUre 2 | Kinetics of antibody responses induced by VsV-based VrP vaccines. Sera from pigs (five animals per vaccine group) that were vaccinated 
with (a) VSV*ΔG(H1), (b) VSV*ΔG(N1), (c) VSV*ΔG, or (D) WIV were collected at the indicated time points, and tested for neutralization (a,c,D) or inhibition of 
viral spread (b) against homologous virus (Belzig/01). At day 28, all animals received a booster immunization. Arrows indicate the vaccination time points. Each 
symbol represents a different animal. Asterisks indicate significant differences between groups at particular days post-vaccination calculated with the Wilcoxon 
test (p < 0.05).
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10−5 (Figures 1E,F). The two H3N2 viruses tested showed differ-
ent phenotypes. While R325/09 was not opsonized by any serum 
(Figure 1G), Flanders/98 was opsonized by anti-H1 and anti-N1 
sera at dilutions of 10−3 and 10−4, respectively (Figure 1H). With 
some of the viruses, “bell-shaped” titration curves of the opzoniz-
ing titers were found. A possible explanation for the lower INF-α 
at the lower 10−2 dilutions could be inhibitory effects of antibodies 
preventing endosomal fusion of the virus, resulting in reduced 
sensing by the cells. These antibody specificities could be diluted 
out along the titration.
These opsonization experiments were repeated several times 
in independent experiments, and the results are shown in 
Figures 1I–K for the sera obtained from the different vaccines. 
Based on these results, we selected the R757/10 for challenge 
infection experiments as this virus was efficiently opsonized but 
not neutralized by sera generated against H1 and WIV, while anti-
NA serum did not show and cross-reactivity. We confirmed the 
ability of anti-H1 to bind to R757/10 using infected MDCK cells. 
Antisera directed to Belzig/01 HA bound to both Belzig/01- and 
R757/10-infected cells, whereas sera directed to Belzig/01 NA 
reacted exclusively with Belzig/01-infected cells (Figure S1 in 
Supplementary Material).
Kinetics of antibody responses induced 
by VsV-based VrP Vaccines
We next vaccinated pigs in groups of five with either 
VSV*ΔG(H1), VSV*ΔG(N1), or WIV, with all antigens derived 
from Belzig/10. A control group of five animals was vaccinated 
with VSV*ΔG, and three animals were not injected. Following a 
booster injection at day 28, VSV*ΔG(H1) and WIV vaccinated 
animals developed good Belzig/01-neutralizing antibody titers 
and VSV*ΔG(N1) antibodies that inhibited Belzig/01 spread. 
VSV*ΔG(H1) induced the highest levels of neutralizing antibod-
ies in all five animals of the group, whereas only one pig from 
the WIV-vaccinated vaccinated group reached similar high levels 
of neutralizing antibodies. No anti-IAV immune response was 
found in pigs vaccinated with VSV*ΔG (Figures 2A–D).
body Temperature and Pathology 
Following heterologous challenge
At day 42 post-vaccination, pigs were infected with R757/10. No 
coughing or increased breathing was observed, and only a mild, 
transient increase in body temperature was recorded (Figure 3). 
On day 2 p.i., the mean body temperature in the VSV*ΔG(H1), 
VSV*ΔG(N1), and VSV*ΔG groups was higher than the mean 
body temperature of non-infected pigs. Nevertheless, statisti-
cal analysis did not reveal significant differences between the 
groups.
Three days p.i., all animals were slaughtered and the lungs 
were analyzed macroscopically and histologically. Generally, 
pathological lesions were mild reaching a maximum macroscopic 
lung score value of 18/100. Nevertheless, the macroscopic lung 
alterations were significantly more severe in animals vaccinated 
with VSV*ΔG(N1) or VSV*ΔG than in pigs vaccinated with 
VSV*ΔG(H1) or WIV (Figure  4A). Histological analysis con-
firmed mild lesions in the lungs of animals with the highest 
macroscopical lung scores (Figure  4B). The histopathological 
findings were typical for influenza virus-induced lesions of 
an acute broncho-interstitial pneumonia. Lesions were mainly 
located in the bronchiole and characterized by epithelial necrosis, 
mild fibrin exsudation and filling of bronchiole with neutrophils. 
Adjacent alveoli were atelectatic or filled with erythrocytes, fibrin, 
and neutrophils (Figure S2 in Supplementary Material). Animals 
vaccinated with VSV*ΔG(H1) had significantly lower histologi-
cal lung scores when compared with animals that had received 
either VSV*ΔG or VSV*ΔG(N1).
Viral rna loads Following challenge 
infection
At day 1 p.i., viral RNA quantities in oronasal swabs were 
significantly lower in animals vaccinated with VSV* ΔG(H1) 
compared with those vaccinated with VSV*ΔG (p  =  0.02) 
(Figure 5A). The other three groups did not significantly differ 
from the VSV* ΔG control group at day 1 p.i. On day 2, no 
differences between the groups could be observed; however, 
FigUre 3 | body temperature following heterologous challenge with 
r757/10. VSV*ΔG(H1)-, VSV*ΔG(N1)-, VSV*ΔG-, or WIV-vaccinated animals 
were challenged with R757/10 (H1N2). In (a), mean values and SDs of body 
temperatures are shown for each group. In (b), values for individual animals 
are shown for day 2 p.i.
FigUre 4 | lung lesions after heterologous challenge with r757/10. Lung lesions were assessed (a) macroscopically and (b) microscopically from each lobe 
at 3 days p.i. Scores were determined by a pathologist who was blinded for the treatments and assessed for each lobe. The values were pooled to one value per 
animal. Asterisks indicate significant differences calculated with the Wilcoxon test (p < 0.05).
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at day 3 p.i., the VSV*ΔG(H1)-vaccinated animals showed 
significantly lower viral loads (Figures  5B,C; p  =  0.047). 
Likewise, in bronchoalveolar lavages, viral RNA copies were 
lower at day 1 p.i. if the animals had been vaccinated with 
VSV*ΔG(H1) as compared with the VSV*ΔG control group 
(Figure  5D; p =  0.042). On day 3 p.i., viral load increased 
in all groups but remained lower in H1-vaccinated animals 
(Figure  5E; p =  0.03). In lung tissue (Figure  5F) as well as 
in the draining bronchial lymph node (data not shown), no 
significant differences were observed between the four vaccine 
groups.
cytokine responses Following 
challenge infection
As local and systemic inflammatory cytokine and IFN-α 
responses may also reflect levels of virus replication, we analyzed 
such responses as an additional indicator of vaccine-induced 
protection (23, 24). Altogether, relating to the relatively mild 
disease, systemic IFN-α remained at low levels during the whole 
observation period (Figure 6). At day 1 p.i., all animals showed 
only low levels of IFN-α; however, in both H1- and N1-vaccinated 
animals, the levels were significantly lower than in the VSV*ΔG 
control group (Figure 6A; p = 0.022). At days 2 and 3 p.i., only the 
VSV*ΔG(H1)-vaccinated animals stayed at significantly lower 
cytokine levels than the control group (Figure 6B; p = 0.002 and 
p = 0.01, respectively). Nevertheless, IFN-α was not completely 
controlled as serum levels in VSV*ΔG(H1)-vaccinated pigs that 
were significantly higher than those in non-infected controls at 
day 3 p.i. In BAL collected at days 1 and 3 p.i. and also in lung 
tissue, no significant differences in IFN-α levels were observed 
between all groups (Figures 6D–F). In contrast to this, significant 
differences were found in lung tissue with respect to inflammatory 
cytokines. VSV*ΔG(H1)-vaccinated pigs had significantly lower 
levels of IL-6 when compared with the VSV*ΔG control group 
(p = 0.01) (Figure 6G). The IL-1β levels in the VSV*ΔG(H1) group 
were significantly lower than those in the VSV*ΔG (p = 0.02) and 
VSV*ΔG(N1) group (p = 0.04) (Figure 6H). Neither IL-1β nor 
IL-6 was increased in the serum and BAL fluid (data not shown).
VrP but not WiV-induced Dual-Functional 
cD4 Th cells secreting iFnγ and TnFα
Given that both the VSV*ΔG(H1) and the WIV vaccine-induced 
opsonizing antibodies reactive with the challenge virus while 
FigUre 5 | Viral rna loads after heterologous challenge with r757/10. Viral RNA copies per milliliter were assessed by RT-qPCR in swabs on days 1 (a), 2 
(b), and 3 (c), in the BAL fluid on day 1 (D) and day 3 (e), and in the lung tissue on day 3 (F). Asterisks (*) indicate significant differences calculated with the 
Wilcoxon test (p < 0.05).
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only the VSV*ΔG(H1) vaccine-induced partial protection, we 
questioned if this would be related to differences in the ability 
to induce T-cell responses. Therefore, PBMCs collected 3 weeks 
post-booster vaccination were restimulated in  vitro with IAV, 
and CD4 and CD8 T cell subsets were analyzed for their ability 
to produce IFNγ and TNFα using multicolor flow cytometry 
(see Figure S3 in Supplementary Material for gating strategy 
and raw data). In Figure 7, virus-specific CD4 T cell responses 
are shown. In animals vaccinated with WIV, only IAV-specific 
TNFα-producing CD4+ T cells were found (p  =  0.008). In 
contrast, stimulation of PBMC that were collected from the 
VSV*ΔG(H1) vaccine groups resulted in a significant produc-
tion of IAV-specific IFNγ (p = 0.03), TNFα (p = 0.02), and dual 
IFNγ- and TNFα-producing (p =  0.03) CD4+ T cells. PBMC 
from VSV*ΔG-vaccinated control animals did not show any 
significant IAV-specific reaction upon restimulation (Figure S3 in 
Supplementary Material). No response was detected in the CD8+ 
T cell subset in any of the groups. We also tested PBMC prior to 
vaccination and found no IAV-specific IFNγ or TNF response 
(data not shown).
Taken together, our results indicate that only VSV*ΔG(H1) 
vaccinated animals were partially protected (summarized in 
Table 2). This was based on the ability of the vaccine to reduce 
macroscopic and microscopic lung lesions, viral RNA loads in 
swabs and BAL fluids, systemic IFNα responses, and local inflam-
matory cytokine induction, although the viral loads in the lungs 
were not significantly reduced. A possible explanation for this 
discrepancy could be that, by chance, we picked areas the lung 
with little virus replication, as virus load can greatly vary in dif-
ferent regions of the pig lung. The immune responses correlating 
with partial protection were characterized by the induction of 
opsonizing antibodies and the presence of CD4 T helper cells in 
the peripheral blood, which secreted both IFNγ and TNFα.
DiscUssiOn
Due to constant antigenic drift and occasional antigenic shift, the 
continuous selection of vaccines matching circulating strains rep-
resents a critical issue with respect to vaccine-induced protective 
immunity. This is further complicated by recent observations in 
human and pigs demonstrating that pre-existing immunity lack-
ing neutralizing antibodies can enhance respiratory disease. In 
human, enhanced disease was first described with the emergence 
of the pandemic H1N1 strain in 2009. Affected patients were char-
acterized by the presence of high titers of antibodies that bound 
to the pandemic strain but were unable to neutralize it, and this 
was associated with pulmonary deposition of immune complexes 
(11). Furthermore, reports from Canada indicated that patients 
who were vaccinated in 2008/09 with WIV had an increased risk 
of severe illness if they were infected with pandemic H1N1 in 
2009 (25). Similar observations were made with Chinese patients 
in 2009. Severe influenza disease in these patients was apparently 
related to high levels of non-neutralizing antibodies as detected 
by ELISA (9). After these reports had been published in 2010, we 
initiated our studies with the aim to investigate the role of non-
neutralizing opsonizing antibodies against HA in the pig model. 
FigUre 6 | innate cytokine responses after heterologous challenge with r757/10. In (a–c) IFNα levels were determined by ELISA in the serum of the 
infected animals on days 1 (a), 2 (b), and 3 (a) post-infection. (D,e) show the IFNα levels in the BAL on day 1 and 3, respectively. In (F–h) cytokine levels were 
determined in lung tissue lysates obtained on day 3 post-challenge. “CTRL” stands for samples obtained from non-infected SPF pigs from the same breeding. Each 
symbol represents a different animal. Asterisks (*) indicate significant differences calculated with the Wilcoxon test (p < 0.05).
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Opsonizing antibodies were detected according to their ability to 
enhance cytokine responses in pDC. The evaluation of clinical, 
virological, and immunological parameters demonstrated that 
the WIV vaccine had no protective effect, neither did it enhance 
disease. In contrast, the VSV*ΔG(H1) VRP vaccine-mediated 
partial protection. As both vaccine types induced opsonizing 
antibodies, we conclude from these findings that opsonizing anti-
body responses can neither be taken as a correlate of enhanced 
disease nor of partial protection.
Our study appears to be in contrast with a series of publications 
describing enhanced disease in pigs that were vaccinated with a 
H1N2 WIV and challenged with a 2009 pandemic H1N1 strain. 
The authors found that vaccination with WIV potentiated clinical 
signs, lung inflammation, and release of inflammatory cytokines 
but had no effect on viral loads (7, 8). It is also important to note 
that enhanced disease was reported with challenge viruses other 
than virus strains from the 2009 pandemic (26, 27). Furthermore, 
other groups have employed a 2009 pandemic strain as heterolo-
gous challenge virus and found no evidence for enhanced disease 
(28). Interestingly, enhanced disease has been observed only with 
WIV and subunit HA vaccines but was not observed with live 
attenuated virus vaccines and an HA-recombinant adenovirus 5 
vector vaccine (8, 27, 29), suggesting that enhanced immunity 
may occur if a mismatched vaccine lacks sufficient priming of 
T cell-mediated immunity. Furthermore, a recent study dem-
onstrated that enhanced diseases were only found when the NA 
was mismatched and thus not able to contribute to protection 
(30). Nevertheless, enhanced disease seems to be a relatively rare 
event occurring only with a particular strain of porcine IAV. The 
present study and other vaccine studies performed with WIV in 
Table 2 | summary of vaccine-induced effects compared with VsV*Δg.
VsV*Δg_ha VsV*Δg_na WiV
Body temperature None None P = 0.019
Macroscopical lung lesions Reduction None Reduction
Histological lung lesions Reduction None None
Viral RNA loads in swabs Reduction None None
Viral RNA loads in BAL Reduction None None
Viral RNA loads in lung tissue None None None
IFNα in serum Reduction None None
IFNα in BAL None None None
IL-6 in lung tissue Reduction None None
IL-1β in lung tissue Reductiona None None
aWhen compared with VSV*ΔG_NA; p = 0.04.
FigUre 7 | Peripheral blood cD4 T-cell responses induced by VsV-based VrP and WiV vaccines. PBMCs were isolated at 3 weeks post-booster 
vaccination and restimulated with chicken allantoic fluid (CAF) as a mock control or IAV in vitro to determine the percentage of virus-specific IFNγ- (a), TNFα- (b), 
and dual cytokine (c) producing cells in the CD4 T cell subset. The percentage of virus-specific cytokine producing cells was determined by subtracting the values 
of the CAF controls from the IAV-stimulated cultures. The gating strategies and CAF/IAV percentages are shown in the Figure S3 in Supplementary Material. 
Asterisks (*) indicate significant differences calculated with the two-way Mann–Whitney U test (p < 0.05).
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pigs found no enhanced disease despite the absence of vaccine-
induced neutralizing or hemagglutination-inhibition antibodies 
(31, 32).
Non-neutralizing opsonizing antibodies have not only 
been associated with enhanced disease, they have also been 
demonstrated to possess protective potential. In ferrets and 
mice, cross-protection was observed through cross-reactive but 
non-neutralizing antibodies (33). On the one hand, heterologous 
immunity was abrogated in B cell-deficient mice but maintained 
in CD8−/− and perforin−/− mice. On the other hand, passive 
transfer of immune serum conferred protection in naive recipi-
ent mice when subsequently challenged with the 2009 pandemic 
H1N1 virus (33). Furthermore, broadly neutralizing monoclonal 
antibodies against the conserved stalk region of HA required 
FcR to confer protection in a mouse model, an observation not 
found with antibodies directed against the variable head domain 
of HA (34).
An important finding of our study is that the VSV*ΔG(H1) 
VRP vaccine provided better protection than WIV. On the 
one hand, the VRP vaccine induced higher levels of antibodies 
compared with WIV, at least in terms of homologous neutraliza-
tion. On the other hand, only after vaccination with the VRP 
vaccine antigen-specific CD4 T helper cells secreting both IFNγ 
and TNFα could be detected in the blood. CD4 T cell responses 
play an important role in the protection against IAV (35, 36). For 
example, in mouse models, they are able to confer protection 
independently of B cells and CD8 T cells (37), and in humans, 
protection was correlated with preexisting influenza-specific 
CD4 T cells (38). Interestingly, CD4 T cells directed against HA, 
but not NP, were found to correlate well with the development of 
neutralizing antibody responses (36, 39). Although HA is much 
less conserved than NP, CD4 T cells primed during an H1 virus 
infection were found to react with even different subtypes, such 
as H5 and H7 (40, 41). Finally, multifunctionality of CD4 T cells 
has also been correlated with protective immune responses (42). 
All these previous findings are in line with the possibility that the 
partial protection against mismatched virus was induced by the 
superior activation of IAV-specific CD4 T cells by VRP vaccine.
In summary, this work demonstrates that WIV vaccines, 
which induce opsonizing antibodies lacking neutralizing activity, 
induce enhanced disease only in certain conditions, which are 
not yet well understood. Furthermore, we demonstrate with the 
virus pair selected that VSV-based VRP vaccines previously used 
successfully for protection of chickens from infection with avian 
IAV (14, 43) are also promising in swine as they induced both 
antibodies and T-cell immunity.
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FigUre s1 | cross-reactivity of anti-belzig/01 ha sera with cell surface 
expressed r757/10 ha. Flow cytometry histogram plots demonstrating the 
binding of sera from VSV*∆G(H1) and VSV*∆G(N1) vaccinated pigs to Belzig/01 
and R757/10 infected MDCK. Similar results were obtained with sera from a 
second vaccinated pig.
FigUre s2 | histological lesions induced by r757/10 challenge. Histological 
sections (overview left, higher magnification right) of representative lung samples 
showing no lesions (a,b), very mild (c,D), mild (e,F), or moderate (g,h) lesions 
typical for viral induced damage to bronchiole and resulting inflammatory reaction. 
Sections in (a–D) derived from a pig of the VSV*∆G(H1) group, whereas lesions 
depicted in (e–h) derived from VSV*∆G(N1) vaccinated pig. Asterisks mark 
bronchiole, arrows point out epithelial damage, neutrophilic inflammation, fibrin 
exsudation in bronchioli. Note that depending on the severity of the lesion, 
adjacent alveoli within the corresponding lobulus were either mainly unaffected 
(c,D) or showed accumulation of edema fluid and neutrophils (e,F) or were 
completely atelectatic (g,h). Staining: H&E, Bars: 500 µm (left), 100 µm (right).
FigUre s3 | Peripheral blood cD4 T-cell responses induced by  
VsV-based VrP and WiV vaccines. PBMC were isolated at 3 weeks post-
booster vaccination and restimulated with CAF (c) or IAV (V) in vitro to determine 
the percentage of virus-specific IFNγ-, TNFα-, and dual cytokine-producing 
cells in the CD4 and the CD8 T cell subsets. In (a), the gating strategy for live 
cells and single cells and CD4 or CD8 cells is shown. On the left side of (b–e), 
representative IFNγ/TNFα dotplots for each vaccination group are shown for 
CD4 T cells. On the right side of (b–e), the percentages of IFNγ-, TNFα-, and 
dual cytokine-producing cells for all animals are shown. Each symbol and color 
represents an individual animal. Asterisks (*) indicate significant differences 
between CAV and virus, calculated with the two-way Mann–Whitney u test 
(p < 0.05). No differences were found with the CD8 T cells (data not shown).
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